Bristol Myers Squibb (BMS) and 2seventy bio have announced plans to discontinue enrolment of subjects in the Phase III KarMMa-9 clinical trial of Abecma (idecabtagene vicleucel) for newly ...

TSVT, BMY Stop Enrollment in KarMMa-9 Study Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified ...

“With a greatly improved NDMM treatment landscape and following our rigorous review of the business case for the KarMMa-9 study, we have decided to discontinue enrollment in this Phase 3 study ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel ...

2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ...

Explaining the decision, the Company's Chief Executive Officer cited "a greatly improved NDMM treatment landscape and . . . our rigorous review of the business case for the KarMMa-9 study".

CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT) and Bristol Myers Squibb (NYSE:BMY) have jointly announced the discontinuation of enrollment in the Phase 3 KarMMa-9 study. The study was ...

The adjustment follows the discontinuation of the KarMMa-9 trial, which was anticipated to be a significant contributor to revenue growth for the autologous BCMA CAR-T therapy, Abecma. According to ...

“With a greatly improved NDMM treatment landscape and following our rigorous review of the business case for the KarMMa-9 study, we have decided to discontinue enrollment in this Phase 3 ...